Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in Pharma and Biotech world.Sanofi beat third-quarter forecasts with a 381% growth in sales of its newly launched respiratory syncytial virus antibody, Beyfortus, bringing in almost $700 million. Analysts expect similar sales in the fourth quarter. Meanwhile, Pfizer CEO Albert Bourla is facing pressure from activist investor Starboard Value, but analysts are supporting him. In other news, Intellia's CRISPR gene editor showed an 81% reduction in hereditary angioedema attacks in a phase II study, while Tyra Biosciences is challenging J&J's Balversa with early data for an FGFR3 blocker in urothelial carcinoma. Trilink Biotechnologies has expanded its mRNA synthesis services offerings with custom sets of mRNA for screening studies. USP aims to double and diversify its volunteer applicant pool for the 2025-2030 cycle, and the CDC has reaffirmed RSV vaccination guidelines. Marinus has had layoffs after a disappointing phase III trial. Other news includes Novo's semaglutide linked to reduced Alzheimer's risk, Massachusetts tax incentives for biotech companies creating jobs, and various job openings in the biopharma industry.